Adjunctive therapy for neonatal abstinence syndrome: why not personalize it for each infant based on their in-utero exposure?

J Perinatol. 2014 Jul;34(7):575-6. doi: 10.1038/jp.2014.99.

Authors

R Singh¹, P F Visintainer²

Affiliations

¹ 1] Division of Neonatology, Department of Pediatrics, Baystate Children's Hospital, Springfield, MA, USA [2] Department of Pediatrics, Tufts University School of Medicine, Boston, MA, USA.
² 1] Department of Epidemiology, Baystate Medical Center, Springfield, MA, USA [2] Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.

PMID: 24968905
DOI: 10.1038/jp.2014.99

No abstract available

Publication types

Letter
Comment

MeSH terms

Adrenergic alpha-2 Receptor Agonists / therapeutic use*
Analgesics, Opioid / adverse effects*
Clonidine / therapeutic use*
Female
Humans
Male
Morphine / administration & dosage*
Neonatal Abstinence Syndrome / drug therapy*
Phenobarbital / therapeutic use*

Substances

Adrenergic alpha-2 Receptor Agonists
Analgesics, Opioid
Morphine
Clonidine
Phenobarbital